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the conclusion of increased hemodilution
severity is CPB based. If the data are rean-
alyzed on the basis of the difference be-
tween preoperative and postoperative CPB
hematocrits, it may be more important that
a decrease in hematocrit of more than ap-
proximately 10% during bypass is associ-
ated with a worse prognosis than discrete
values.
Jeffrey H. Shuhaiber, MD
Department of Surgery
University of Illinois at Chicago
Chicago, Ill
References
1. Habib RH, Zacharias A, Schwann TA, et al.
Adverse effects of low hematocrit during car-
diopulmonary bypass in the adult: should cur-
rent practice be changed? J Thorac Cardio-
vasc Surg. 2003;125:1438-50.
2. Horwich TB, Fonarow GC, Hamilton MA, et
al. Anemia is associated with worse symp-
toms, greater impairment in functional capac-
ity and a significant increase in mortality in
patients with advanced heart failure. J Am
Coll Cardiol. 2002;39:1780-6.
3. Puskas JD, Williams WH, Duke PG, et al.
Off-pump coronary artery bypass grafting
provides complete revascularization with re-
duced myocardial injury, transfusion require-
ments, and length of stay: a prospective ran-
domized comparison of two hundred
unselected patients undergoing off-pump ver-
sus conventional coronary artery bypass
grafting. J Thorac Cardiovasc Surg. 2003;
125:797-808.
4. Levy M, Cromheecke ME, de Jonge E, et al.
Pharmacological strategies to decrease exces-
sive blood loss in cardiac surgery: a meta-
analyses of clinically relevant end points.
Lancet. 1999;354:1940-7.
5. Utley JR, Wilde EF, Leyland SA, et al. In-
traoperative blood transfusion is a major risk
factor for coronary artery bypass grafting in
women. Ann Thorac Surg. 1995;60:570-5.
doi:10.1016/j.jtcvs.2003.09.059
Reply to the Editor:
We thank Dr Shuhaiber for his interest in
our recent article in the Journal.1 We are
encouraged that he concurs with us that
low extremes of hematocrit during cardio-
pulmonary bypass (CPB) should be
avoided and that the strong associations we
reported between excessive hemodilutional
anemia during bypass and adverse patient
outcomes argue for a prospective study. He
also requested methodologic clarifications
and presented several comments that are
worthy of addressing.
Our 5000-patient CPB retrospective se-
ries1 (1994–2000) reflects a population in
whom asanguinous rather than blood prime
fluid was used. In a very small fraction of
patients (anemic patients with low red
blood cell volume), blood may have been
added to the prime at the onset of CPB.
These are included as intraoperative trans-
fusions. Aprotinin was used relatively in-
frequently (7%), and we believe it had
little bearing, if any, on the reported find-
ings. Standard intraoperative cell-saving
methods were used routinely, and saved
cells were returned to patients during or
immediately after CPB. Hemoconcentra-
tion during CPB was used in 16% of pa-
tients.
Perioperative blood-loss amounts were
not prospectively documented in our data-
base and were not reported. Alternatively,
excessive bleeding requiring re-exploration
(Figure 1 and Table 4 of reference 1) and
transfusions (Figure 3 and Table 4 of ref-
erence 1) were reported.1 The “transfusion
trigger” was not rigidly controlled during
the 7-year period of this retrospective se-
ries, and this threshold may have varied
slightly among surgeons and depended on
the patient age and clinical status. We be-
lieve, however, that these variations do not
diminish the clear and obviously strong
relationship between nadir CPB hematocrit
and transfusion rates (Figure 3 of reference
1).
As we reported,1 low pre-CPB hemato-
crit is an important predictor of increased
hemodilution during standard CPB (Table
2 of reference 1), but a history of conges-
tive heart failure (documented in 9% of
patients in this series) is not. Notably, pa-
tients with acute heart failure that is asso-
ciated with anemia as the result of compen-
satory plasma volume expansion almost
never undergo operation in our practice.
Such patient conditions are usually medi-
cally reversed before surgery. Alterna-
tively, intraoperative fluid infusions by an-
esthesia and preoperative blood donation
may lead to substantial plasma volume ex-
pansion that can contribute to the extent of
hemodilution during CPB and should be
carefully considered.
Dr Shuhaiber refers to the randomized
prospective study by Puskas and col-
leagues,2 which compares off-pump and
on-pump bypass operations in 200 patients
and states that the role of intraoperative
hematocrit in off-pump CABG is minimal
because little or no differences in outcomes
are reported. In responding to this point, it
is important to note that off-pump and on-
pump CABG procedures are different in
many ways, one of which is hemodilution
as the result of mixing the patient’s blood
with prime fluid. Although it is true that
Puskas and colleagues reported generally
similar in-hospital and 30-day mortalities,
their data partially support several of our
findings.1 Indeed, they reported less he-
modilution, less transfusion requirements,
less coagulopathy, earlier extubation, de-
creased hospital stays, and less myocardial
injury (cardiac enzyme levels) for their pa-
tients undergoing off-pump CABG versus
on-pump CABG. These results are all in
concert with our findings. The fact that no
significant differences in other important
outcome measures (including mortality)
were found may be partially attributable to
the size of the series.
For the 3,800 isolated patients undergo-
ing CABG in this series, the mean number
of grafts per patient was 3.1  1.0. More-
over, as we report in Results1 on page
1441, operative mortality (defined as in
hospital or out of hospital within 30 days of
surgery) for isolated CABG was 2.4% (90/
3800), a rate slightly lower (rather than
higher) than that cited by Dr Shuhaiber in
the CABG series.3 The 3.6% operative
mortality that he reports reflects the overall
rate for all 5,000 patients, including pa-
tients undergoing valve and combined
CABG and valve operations.
As we stated in our article,1 late mor-
tality follow-up was based on queries of the
Social Security Death Index Database, in
which the cause of death is not available;
thus we could not report the relationship
between hematocrit on CPB and late car-
diovascular death. Nonetheless, Dr Shu-
haiber’s questions about whether graft fail-
ure in CABG is linked to the extent of
hemodilutional anemia or transfusions is
clearly important and worthy of separate
future investigation that is well outside the
scope of our study.
Intuitively, Dr Shuhaiber’s proposition
that the decrease in hematocrit should be
used as the independent (or predictor) vari-
able rather than the actual low hematocrit is
appealing. However, the extent of hemodi-
lution on CPB is multifactorial, as we re-
ported in Table 2.1 Also, our1 and De-
Foe’s4 data clearly demonstrated that a
decrease of 10% or 15% in hematocrit is
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different in patients with pre-CPB hemat-
ocrits of 30% as opposed to 40%. Another
advantage of this approach is that it pro-
vided a means of objectively identifying a
threshold for how low nadir hematocrits
may be tolerated according to outcome data.
Robert H. Habib, PhD
Anoar Zacharias, MD
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Microfibrillar collagen hemostat in
cardiac surgery
To the Editor:
The September 2003 article of S¸ırlak and
associates1 extolled the virtues of microfi-
brillar collagen (MC) as a hemostatic
agent. Studies by our own group support
the conclusion that this compound is highly
effective in cardiac surgery.2 However, I
must sound more than a word of caution.
When in the early 1980s we have ap-
plied MC frequently in the course of heart
operations, we encountered cases of unex-
plained brain injuries. Because we sus-
pected MC as the culprit, the substance was
subjected to extensive in vitro and in vivo
investigation. We found that MC-contain-
ing shed blood, if returned to the circula-
tion by either pump-suction or cell-salvage
devices, may readily pass 40-mm pore-size
filters and lodge in vital organs, including
the brain.3
For this reason, we have recommended
that blood contaminated by MC should not
be reused. Once MC has been applied, only
waste suction should be applied to handle
shed blood.
Francis Robicsek, MD, PhD
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Reply to the Editor:
Despite the use of filters with a pore size of
20 m, the combined use of intraoperative
autotransfusion and microfibrillar collagen
hemostats creates a potential risk for em-
bolization.1 It has been shown that this risk
can be significantly reduced by use of ap-
propriate currently available blood transfu-
sion filters.2 Despite this reduction, we
share the concern of Dr Robicsek that this
substance could pass through different
blood-collecting circuits, which could lead
to organ damage by either direct or induced
embolization, even with the use of com-
mercially available filters.3 For this reason
we applied microfibrillar collagen after
heparin was neutralized by protamine, and
it was not reintroduced into the patient cir-
culation. Moreover, as we stressed in the
Methods section, shed mediastinal blood
was not transfused into any patient.
Mustafa S¸ırlak
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